07:00 , Apr 9, 2012 |  BC Week In Review  |  Company News

RiboCor cardiovascular, musculoskeletal, hematology news

Bioenergy Inc. changed its name to RiboCor and said it will solely focus on medical applications, including development of therapeutics for fibromyalgia and cardiovascular disease, as well as biologics to enhance red blood cell functionality....
07:00 , May 14, 2007 |  BC Week In Review  |  Company News

Atrium Biotechnologies Inc. nutraceuticals news

ATB changed its name to Atrium Innovations Inc. Atrium Biotechnologies Inc. (TSX:ATB), Quebec City, Quebec   Business: Nutraceuticals  ...
08:00 , Jan 15, 2007 |  BioCentury  |  Strategy

Jettisoning revenue

Aeterna Zentaris Inc. expects the $50 million it gained from spinning out its Atrium Biotechnologies Inc. specialty chemicals and nutraceutical division will allow it to get to multiple valuation inflection points in the coming years,...
08:00 , Feb 17, 2005 |  BC Extra  |  Financial News

Atrium Biotechnologies files for IPO

Atrium Biotechnologies (Quebec City, Quebec) filed to go public on the Toronto Stock Exchange. AEterna Zentaris (TSE:AEZ; AEZS) owns 61.1% of Atrium, which markets a portfolio of active ingredients, specialty chemicals and health and nutrition...
08:00 , Jan 31, 2005 |  BC Week In Review  |  Company News

Aeterna Zentaris, Multichem Inc. deal

AEZ's Atrium Biotechnologies Inc. subsidiary (Quebec City, Quebec) acquired Multichem for C$23.8 million (US$19.5 million), including $22.2 million in cash. MultiChem distributes specialty and commodity chemicals in Canada and the northeastern U.S. Aeterna Zentaris Inc....
07:00 , Jul 3, 2001 |  BC Extra  |  Company News

Atrium acquires Unipex

Atrium Biotechnologies (Quebec City, Quebec), a developer of active ingredients for cosmetics, nutrition, pharmaceuticals and chemicals, will acquire 70% of raw materials play Unipex (Paris, France) for C$20 million (US$13.2 million). Unipex management will retain...
08:00 , Mar 5, 2001 |  BC Week In Review  |  Company News

Aeterna board of directors update

Aeterna Laboratories Inc. (TSE:AEL; AELA), Quebec City, Quebec   Business: Cancer   Appointed: Stormy Byorum, managing partner at Pioly, Byorum & Partners, replacing Luc Dupont, who will remain president and CEO of AEL's Atrium Biotechnologies...
07:00 , Oct 9, 2000 |  BC Week In Review  |  Company News

Atrium Biotechnologies Inc. board of directors update

(Management, B9) Atrium Biotechnologies Inc., Quebec City, Quebec   Business: Nutraceuticals   Appointed: Pierre Laurin, executive in residence at Montreal's Ecole des hautes etudes commerciales  ...
07:00 , Oct 9, 2000 |  BC Week In Review  |  Company News

Atrium Biotechnologies Inc. management update

(Board, B8) Atrium Biotechnologies Inc., Quebec City, Quebec   Business: Nutraceuticals   Promoted: Alain Lavole to VP from director of corporate development   Hired: Jocelyn Harvey as VP of finance, formerly director of operations and...
08:00 , Jan 31, 2000 |  BC Week In Review  |  Company News

Aeterna dermatology, foods news

AEL spun out its cosmetics and nutrition businesses into Atrium Biotechnologies, in which AEL will hold a 77.8 percent interest. SGF Soquia Inc. and Fonds de solidarite FTQ invested C$7.5 million (US$5.2 million) and C$2.5...